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Abstract
Background Adenocarcinomas commonly metastasize to
the lungs and can be resected using open thoracotomy or
video-assisted thoracic surgery (VATS). This study
reviews metastatic resections in primary adenocarcinoma
patients, using both thoracotomy and VATS. We aim to
compare long-term prognoses to test the efﬁcacy and via-
bility of VATS.
Methods A retrospective review of primary adenocarci-
noma patients who underwent resection of pulmonary
metastases from 1990 to 2006 was carried out. Information
was obtained by chart review. Endpoints analyzed were
disease-free interval (DFI), survival time, and recurrence-
free survival (RFS).
Results In a total of 42 (16 male, 26 female; median age
58.5 years) primary adenocarcinoma patients, 21 patients
underwent ﬁrst pulmonary metastatic resection using VATS
(7 male, 14 female; median age 57 years) and 21 using tho-
racotomy(9male,12female;medianage59 years).Primary
adenocarcinomas were mainly 27 colorectal (64%) and 11
breast (26%). Two VATS (10%) and three open patients
(14%) had local recurrences of the original cancer. Median
postoperative follow was 13.3 months [interquartile range
(IQR) 4.5–32.8 months] for VATS and 36.9 months (IQR
19.3–48.6 months) after thoracotomy. Median DFI–1 was
22.3 months(IQR13.5–40.6 months)forVATSpatientsand
35.6 months (IQR 26.7–61.3 months) for open patients.
Second thoracic occurrences were noted in six VATS
patients (median DFI–2 9.2 months), and in seven open
patients (median DFI-2 21.5 months). Third thoracic occur-
renceswerenotedinoneVATSpatient(DFI-318.7 months)
and in one thoracotomy patient (DFI-3 21.8 months). Odds
ratio of recurrence showed 12.5% less chance of developing
recurrence in VATS patients. Five-year RFS was 53% in
VATS and 57% in thoracotomy patients.
Conclusions VATS has become a viable alternative to
open thoracotomy for resection of pulmonary metastases.
In cases of primary adenocarcinoma, VATS showed no
increase in number of thoracic recurrences, and comparable
RFS. Short-term follow-up is encouraging; long-term fol-
low-up will be needed to conﬁrm these results.
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Aggressive resection of pulmonary metastasis has become
a more commonly accepted treatment modality for care-
fully selected patients. Since its introduction more than a
decade ago, video-assisted thoracoscopic surgery (VATS)
has been used in the diagnosis of pulmonary nodules and
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nodes, and more recently resection of pulmonary metas-
tasis [1, 2]. Several short-term studies have been published
demonstrating the evolution and utility of VATS for
treating pulmonary cancer [3–6]. However, long-term
outcomes of VATS resection of pulmonary metastases
have not been studied as extensively [7, 8]. The use of
VATS lobectomy for non-small-cell bronchogenic carci-
noma has already shown the potential long-term beneﬁts of
VATS resection of early-stage cancer [9].
Surgical resection of pulmonary metastasis is always
performed with curative intent. Therefore, we consider the
prognostic factors that affect long-term outcome: complete
resection of lung metastasis, longer disease-free interval
between treatment of primary and diagnosis of pulmonary
metastasis, and presence of single or limited number of
metastatic lesions. Depending on the underlying primary
cancer, and the selection criteria for surgery, the expected
5-year survival rate of surgery with curative intent varies
from 30% to 50% [10–12]. The minimally invasive
approach and described advantages of VATS warrant fur-
ther investigation of the utility of VATS over a longer
period of time with careful attention to the above factors.
This study reviews and compares our pulmonary meta-
static resections in patients with primary adenocarcinoma,
using both VATS and open thoracotomy, in an effort to
determinetheefﬁcacyandestablishtheoncologicvalidityof
VATS as an alternative approach to open thoracotomy. This
can help delineate the long-term prognoses and survival
advantages of VATS, as well as offer an opportunity to
deﬁne more absolute indications of VATS for lung cancer.
Materials and methods
Eligibility criteria
Patients eligible for this study were those who underwent
resection of pulmonary metastasis with subsequent follow-
upatUniversityofCalifornia,LosAngeles(UCLA)between
1973 and 2006, and met the following criteria: (1) primary
adenocarcinoma at nonthoracic location, and (2) pulmonary
metastasisfollowingresectionoforconcurrentwithprimary
adenocarcinoma.Exclusioncriteriawere:(1)primarycancer
otherthanadenocarcinoma, (2)thoracicprimarycancer,and
(3) thoracic resection of a nonthoracic occurrence. The
selection of operative procedure varied according to sur-
geon’s preferences, among a total of four surgeons.
Study design
In this comparative study, we retrospectively reviewed
patients who had primary adenocarcinoma with metastasis
to the lungs. Information regarding disease status and
survival was reviewed over the time period deﬁned for
patients with primary adenocarcinoma. This was obtained
by chart review, using the Patient Centric Information
Management System (PCIMS) at UCLA. We determined
whether patients met inclusion and exclusion criteria.
Patients were grouped by operation completed at the time
of ﬁrst resection: video-assisted thoracoscopic surgery
(VATS) or open thoracotomy. Patient demographic infor-
mation collected included age, sex, race, smoking status,
site of primary cancer, use of adjuvant therapy, comor-
bidities, history of other cancer, and pulmonary function
status. Pulmonary function status was categorized as poor,
fair or good.
Patients were also evaluated for having recurrence at the
primary site, metastasis to nonthoracic sites, and pulmon-
ary metastasis. Primary recurrence was deﬁned as
recurrence of primary adenocarcinoma after resection of
the same cancer. Metastases to nonthoracic sites were
deﬁned as cancer at other sites, not including the primary
site or a thoracic site. Thoracic occurrence was deﬁned as
cancer in the lung at any location, and recurrences were
noted as either ipsilateral solitary, ipsilateral multiple, or
bilateral multiple. Regarding thoracic resections, the fea-
tures evaluated included: location of occurrence, surgical
approach, type of lung resection, and use of adjuvant
therapy. Patients with a second and/or third occurrence
were evaluated in the same manner.
Locations of thoracic occurrence were noted as right,
left or bilateral. When recurrence was detected, recurrence
was treated with VATS, thoracotomy or nonsurgically. We
also compare the type of surgical approach used in recur-
rences with the approach used in previous resections.
Lastly, causes of death were considered as thoracic or
nonthoracic.
Baseline and treatment assessments
Patient baseline demographic information was evaluated
for comparability to address the potential for selection bias.
The primary outcome was survival time, deﬁned as date of
ﬁrst pulmonary occurrence to latest follow-up, or death due
to cancer or other cause. The secondary outcome was
recurrence-free survival (RFS), deﬁned as date of ﬁrst
resection to date of second occurrence, death or latest
follow-up with no occurrence between these intervals. The
time intervals noted were: (1) DFI-1, disease-free interval
between diagnosis of primary adenocarcinoma and diag-
nosis of ﬁrst pulmonary metastasis; (2) DFI-2, time interval
between ﬁrst and second occurrences; (3) DFI-3, time
interval between second and third occurrences; (4) total
disease interval (TDI), the start time for which was original
diagnosis of primary cancer, and the terminal event was
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123latest follow-up, or date of death; and (5) postoperative
follow-up, deﬁned as date of ﬁrst resection to latest follow-
up.
Statistical analysis
All data are reported as median or frequencies, with
associated interquartile ranges (IQR), 95% conﬁdence
intervals (CI), and p-values calculated. Categorical data,
both nominal and ordinal, were compared between groups
using Fisher’s v
2 (exact) test. Continuous data were com-
pared for differences using Mann–Whitney U-test. Survival
analysis and recurrence-free survival were calculated
according to Kaplan–Meier method. Two-tailed p-values
with p\0.05 were considered statistically signiﬁcant. All
statistical analyses were performed using MedCalc.
Results
Patient characteristics
Between 1973 and 2006, there were a total of 182 patients
who underwent resection of lung metastasis at our insti-
tution. Forty-two of the 182 patients ﬁtted the eligibility
criteria and had at least one resection of a pulmonary
metastasis during the time period between 1990 and 2006.
Of these 42 patients, ﬁrst pulmonary resection was per-
formed by VATS in 21 patients and by open thoracotomy
21 patients. Resection of subsequent pulmonary occurrence
was either the same or a different procedure than the ﬁrst
one: VATS or thoracotomy or nonsurgical.
Patients were comparable in terms of most baseline
patient characteristics. Demographics of the 42 patients
with primary nonthoracic adenocarcinoma are listed in
Table 1. Tests for homogeneity did not show statistically
signiﬁcant differences between the two groups. Median age
was 58.5 years for all patients. The majority of participants
were female and Caucasian in both groups. There were
more nonsmokers than smokers (p = 0.76). Post hoc
analysis of sample size (a = 0.05, power 0.8) was 42
calculated by survival from ﬁrst thoracic occurrence, and
34 calculated by RFS.
Site of primary adenocarcinoma was primarily colo-
rectal and breast in both groups (p = 0.66). The other few
were hepatic (n = 1), ovarian (n = 1), pancreatic (n = 1),
and cervical (n = 1). Some patients also had nonthoracic
metastasis (p = 0.21). Few patients had local recurrence of
original cancer, with only two in the VATS group and three
in the open group (p = 0.63). Metastatic lesions were more
commonly located on the right side (p = 0.51). Of the ﬁrst
thoracic occurrence, unilateral solitary, unilateral multiple,
and bilateral multiple lesions occurred in 43% (n = 9),
33% (n = 7), and 24% (n = 5) in the VATS group,
respectively, and 14% (n = 3), 71% (n = 15), and 14%
(n = 3) in the open group, respectively. Adjuvant therapy
was received in 11 (52%) patients in the VATS group, and
in 8 (38%) patients in the thoracotomy group (p = 0.54).
Follow-up was complete by December 2006. Median
follow-up period from primary diagnosis was 59.9 months
(IQR32.9–96.87 months),and27.4 months(IQR4.87–39.9
Table 1 Demographics of patients at initial pulmonary metastasis
VATS
(n = 21)
Open
(n = 21)
p-value*
Age
a (years) 57 59 0.78
IQR 47–68.8 52.3–63.5
95% CI 47–68.51 52.49–63.34
Sex 0.75
Female 14 (67) 12 (57)
Male 7 (33) 9 (43)
Race 0.72
Caucasian 17 (81) 15 (71)
Non-Caucasian 4 (19) 6 (29)
Smoker 0.76
Yes 10 (48) 8 (38)
No 11 (52) 13 (62)
History of other cancer 1.0
Yes 3 (14) 3 (14)
No 18 (86) 18 (86)
Comorbidity
Single comorbidity 12 (57) 8 (38) 0.35
Three comorbidities 4 (19) 2 (10) 0.66
Functional status 1.0
Poor 1 (5) 0 (0)
Fair 0 (0) 0 (0)
Good 20 (95) 21 (100)
Primary cancer 0.49
Colorectal 12 (57) 15 (71)
Breast 6 (28) 5 (24)
Other 3 (14) 1 (5)
Metastases
At diagnosis of primary 2 (10) 2 (10) 1.0
Nonthoracic mets
b 6 (29) 11 (52) 0.21
Recurrence of primary 2 (10) 3 (14) 1.0
Site ﬁrst thoracic mets 0.54
Bilateral 5 (24) 3 (14)
Left 5 (24) 8 (38)
Right 11 (52) 10 (48)
Deaths 7 (33) 5 (24) 0.73
* Two-tailed p-value; p\0.05 was considered statistically
signiﬁcant
a All data are reported as no. (%) unless speciﬁed otherwise
b Mets, metastases
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123months) from ﬁrst thoracic occurrence. No patient was
lost to follow-up in either group. Median TDI was shorter
in the VATS group, and this difference was statistically
signiﬁcant (p = 0.03). VATS follow-up since ﬁrst resec-
tion was shorter compared with follow-up in thoracotomy
(13.3 versus 36.9 months), although not statistically
signiﬁcantly so.
Tumor response: patients with second occurrence
Second thoracic occurrences were noted in six VATS
patients; three of these patients had VATS initially then
had nonsurgical treatment of second occurrence, two with
chemotherapy and one with no speciﬁed adjuvant treatment
(median DFI-2 84 days). Patient characteristics are listed in
Table 2. Another three VATS patients were initially treated
with VATS then had second occurrence treated with open
thoracotomy (median DFI-2 386 days). One of the latter
three patients had the second VATS procedure converted to
open thoracotomy the next day in order to remove a dense
mass due to adhesions. No adjuvant therapy was given. A
seventh patient had a second thoracic procedure performed;
however, this patient was excluded from the second
occurrence group because the second thoracic resection
was an excision of a noncancerous mass.
A second occurrence was noted in seven open patients
(median DFI-2 655 days). Four of the seven patients were
subsequently treated with thoracotomy a second time
(median DFI-2 585 days), one patient with chemotherapy
alone (DFI-2 655), one with VATS (DFI-2 26 days), and
one with radiofrequency ablation (DFI-2 708 days).
In both groups, none of the patients had recurrence of
the primary cancer. All patients in the VATS group were
nonsmokers. In the open thoracotomy group, ﬁve were
nonsmokers and two were smokers. Recurrences in the
VATS group were two (33%) ipsilateral solitary metasta-
sis, one (17%) ipsilateral multiple metastasis, and three
(50%) bilateral metastases; and recurrences in the open
group were ﬁve (71%), one (14%), and one (14%),
respectively (p = 0.47).
Tumor response: patients with third occurrence
A total of three patients in this study had a third resection,
however only two of the three had a thoracic recurrence.
The patient who had conversion of the second VATS to
thoracotomy to remove a dense mass due to adhesions was
excluded from the third occurrence group. The VATS
patient with a third occurrence (DFI-3 569 days) did not
have metastasis outside the lung. Site of ﬁrst pulmonary
occurrence was on the left side and was treated with VATS
without adjuvant therapy. The second occurrence, located
on the right, was treated with thoracotomy without adju-
vant therapy, and the third occurrence, located on the left,
was treated with VATS without adjuvant therapy. This
patient was still alive at latest follow-up, 40 months since
ﬁrst thoracic occurrence.
Table 2 Demographics of patients with second occurrence
VATS (n = 6) Open (n = 7) p-value*
Age
a (years) 52 55 0.37
IQR 40–57 51–60.3
95% CI – 46.01–63
Sex 1.0
Female 5 (83) 5 (71)
Male 1 (17) 2 (29)
Race 1.0
Caucasian 4 (67) 4 (57)
Non-Caucasian 2 (33) 3 (43)
Smoker 0.46
Yes 0 (0) 2 (29)
No 6 (100) 5 (71)
History of other cancer 0.46
Yes 0 (0) 2 (29)
No 6 (100) 5 (71)
Comorbidity
Single comorbidity 1 (17) 2 (29) 1.0
Three comorbidities 0 (0) 1 (14) 1.0
Functional status 1.0
Poor 0 (0) 0 (0)
Fair 0 (0) 0 (0)
Good 6 (100) 7 (100)
Primary cancer 0.33
Breast 3 (50) 1 (14)
Colorectal 2 (33) 5 (71)
Other 1 (17) 1 (14)
Metastases
At diagnosis of primary 1 (17) 1 (14) 1.0
Nonthoracic mets
b 2 (33) 6 (86) 0.10
Recurrence of primary 0 (0) 1 (14) 1.0
Site ﬁrst thoracic mets 0.72
Bilateral 2 (33) 3 (42)
Left 3 (50) 2 (29)
Right 1 (17) 2 (29)
Site second thoracic mets 0.33
Bilateral 3 (50) 1 (14)
Left 1 (17) 1 (14)
Right 2 (33) 5 (71)
Deaths 2 (33) 2 (29) 1.0
* Two-tailed p-value; p\0.05 was considered statistically
signiﬁcant
a All data are reported as no. (%) unless speciﬁed otherwise
b Mets, metastases
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occurrence (DFI-3 663 days). The ﬁrst surgery, involving
both sides, was a median sternotomy with three wedge
resections and no adjuvant therapy. The second occurrence,
located on the right, was treated with thoracotomy with
adjuvant radiation therapy. The third occurrence, located
on the left side, was treated with thoracotomy without
adjuvant therapy. This patient also had metastasis outside
the lung, in the pancreas and spleen after treatment of his
primary cancer. This patient had past history of renal cell
cancer. This patient is still alive, 62.3 months since ﬁrst
thoracic occurrence.
The primary tumor was colorectal in both patients. Both
were nonsmokers, with no comorbidities, and no recur-
rence of primary tumor. Second and third occurrences were
at distant sites from the ﬁrst occurrence.
Time to events
Median DFI-1 was 22.3 months for VATS patients, shorter
than for open patients (p = 0.07). Median DFI-2 and DFI-3
were also shorter for the VATS group, although a statistical
difference was not found (Table 3).
Overall survival
There were seven deaths in the VATS group, three non-
thoracic and four of unknown cause; and ﬁve deaths in the
open group, two nonthoracic and three of unknown cause.
The 1-, 3-, and 5-year survival rates after ﬁrst pulmonary
resection were 70%, 54%, and 54% for VATS, respec-
tively, and 100%, 94%, and 78% for thoracotomy,
respectively (p = 0.14, Fig. 1). Corresponding median
overall survival was 13.3 months in the VATS group, and
36.9 months in the open group (p = 0.10). After 6 years
since initial metastasectomy, survival dropped to 26% in
the thoracotomy group, but remained at 54% for the VATS
group. Among the patients with a single pulmonary
metastasis and resection, most deaths occurred within the
ﬁrst year in the VATS group, with 1-year survival of 64%
and 5-year survival of 55%. The 1- and 5-year survival
rates in the open thoracotomy group were 100% and 77%,
respectively, although survival dropped to 39% after
6 years in this group (p = 0.23).
Recurrence-free survival
A total of six patients in the VATS group had more than
one thoracic occurrence (n = 7), and median RFS was
8.6 months (Table 3). In the thoracotomy group, there
were 7 patients (n = 8), and median RFS was 25.1 months.
The VATS group showed no recurrences after 32 months,
and the open group showed none after 35 months. Esti-
mated RFS rate at 5 years and beyond was 53% in the
VATS group, and 57% in the open thoracotomy group
(p = 0.77, Fig. 2). The odds ratio for recurrence shows a
12.5% less chance of developing recurrences in the VATS
patients (Table 4). Two thoracotomy patients developed
recurrence within the ﬁrst 30 days after initial
Table 3 Time intervals
* Two-tailed p-value; p\0.05
was considered statistically
signiﬁcant
a All data are reported as
months (IQR) unless speciﬁed
otherwise
VATS Open p-value*
Follow-up (1990–2006)
a
Total disease interval 50.7 (23.3–69.8) 80.6 (47.7–121.3) 0.03
Postoperative follow-up 13.3 (4.5–32.8) 36.9 (19.3–48.6) 0.10
Disease-free intervals
DFI–1 22.3 (13.5–40.6) 35.6 (26.7–61.3) 0.07
DFI-2 9.2 (2.7–16.3) 21.5 (4.6–23) 0.53
DFI-3 18.7 21.8 1.0
No more recurrences after 32 35
Survival
Recurrence-free survival 8.6 (3.1–27.7) 25.1 (0.8–40.2) 0.33
Overall survival 13.3 (4.5–32.8) 36.9 (19.3–48.6) 0.10
Fig. 1 Overall survival after initial metastasectomy, all patients
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Three VATS patients developed recurrence between
1 month to 1 year. Most recurrences occurred within the
ﬁrst 2 years in both groups (six open, ﬁve VATS). Post hoc
power analysis showed 69% power in recurrence-free
survival equality analysis, and 61% power in overall sur-
vival equality analysis (a = 0.05, double sided).
Discussion
Key results
Various studies have demonstrated the beneﬁts of VATS
over open thoracotomy, making VATS a favorable
modality to treat cancer: less invasive with a decreased
amount of chest wall trauma, less pain, less inﬂammatory
response and smaller degree of immunosuppression,
shorter hospital stay, accelerated postoperative recovery,
decreased long-term morbidity, and better long-term
functional level [2, 13]. These features, however, have
been demonstrated over a short-term period, and it is not
yet well documented whether the long-term advantages are
comparable to standard open thoracotomy. Recognizing
that complete resection remains a main determinant of
survival, this study reviewed outcomes of primary non-
thoracic adenocarcinoma with pulmonary metastasis
treated with either VATS or open thoracotomy to initiate
the evaluation of the long-term outcomes of VATS and its
adequacy for cancer surgery.
This study is derived from a reasonably extended fol-
low-up period of 59.9 months. During the period under
study, 23 VATS and 29 thoracotomy procedures were done
in 42 patients. Our data estimates 5-year overall survival
rate from ﬁrst thoracic occurrence at 54% for the VATS
group and 78% in the thoracotomy group. Despite this
difference, survival in the VATS patients is comparable to
that in previous short-term studies. Data from the literature
[10–12, 14–17] suggest that 5-year survival after resection
of pulmonary metastasis with thoracotomy ranges from
32% to 50%. After 6 years since initial metastasectomy,
the survival rate remained at 54% in the VATS group, but
dropped to 26% in the open thoracotomy group. Deaths
unrelated to cancer were also included in the analysis of
overall survival, which could account for the differences in
survival rate. In our study, none of the deaths in the VATS
group or the thoracotomy group were due to thoracic
causes.
We also evaluated recurrence-free survival since we
were interested in recurrence of cancer. Those patients with
a second or third occurrence had subsequent resection with
the same or other procedure. Our data show 5-year recur-
rence-free survival rate of 53% in VATS (n = 7), which is
comparable to that in open thoracotomy (57%, n = 8).
Corresponding median RFS from second and third occur-
rence was 8.7 and 25.5 months, respectively. In this study,
the odds ratio of 0.86 showed that recurrence is 12.5% less
likely in the VATS patients.
Statistical analysis demonstrated that the two groups
were similar in terms of patient characteristics, enabling us
to make clinically and statistically relevant comparisons.
We selected patients with primary adenocarcinoma who
underwent either VATS or open thoracotomy for resection
of ﬁrst pulmonary metastasis. From post hoc analysis
(a = 0.05, power 0.8), the sample size in our study is
considered adequate.
Fig. 2 Recurrence-free survival after initial metastasectomy, all
patients
Table 4 Survival after median follow-up of 59.9 months from primary diagnosis (27.4 months from initial metastasectomy)
VATS (n = 21) Open (n = 21) Odds ratio
(VATS versus open)
95% CI p-value*
Total recurrences
a 7 (33) 8 (38) 0.88 0.39–1.98 0.50
Overall survival 14 (67) 16 (76) 1.4 0.52–3.71 0.37
Recurrence-free survival 15 (71) 14 (67) 0.86 0.35–2.12 0.50
* Two-tailed p-value; p\0.05 was considered statistically signiﬁcant
a All data are reported as no. (%) unless speciﬁed otherwise
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123Interpretation
Surgical removal of lung metastasis is performed with
curative intent, and has proven to be a therapeutic option.
Virtually any tumor can metastasize to the lung, with
colorectal, breast, head and neck, thyroid, and renal cell
cancers among the most likely to spread to the lungs [18].
Our results parallel these ﬁnding. In this study, colorectal
and breast cancer were the most common primary tumors
that metastasized to the lungs, with 57% and 28% in the
VATS group, and 71% and 24% in the open group,
respectively. The two patients with a third occurrence had
primary colorectal cancer.
The most common form of secondary lung tumors are
metastatic malignant neoplasms, with the subpleural or
outer third of the lung ﬁelds as the most common site, and
the most typical appearance as well-circumscribed non-
calciﬁed nodules. In both groups, pulmonary metastasis
was more common in the right lobe. One patient in the
open group had a single recurrence that was subsequently
treated with VATS, and no further recurrence was noted in
this patient. Whether this is a manifestation of the type of
surgery performed or the inherent behavior of the primary
cancer is not clearly delineated. However, given the
favorable features of VATS and that metastasis to the lung
frequently presents as a solitary pulmonary nodule occur-
ring at a single site, this study supports that pulmonary
metastasis can still be considered very amenable to resec-
tion using VATS. Furthermore, with use of spiral computed
tomography (CT) scan to localize metastases for surgical
planning, lesions can be accurately identiﬁed, in contrast to
with older CT scans that missed lesions, allowing VATS to
be successful [19, 20].
A major concern regarding the use of VATS with
malignancy would be potential for increased incidence of
local or distant recurrence. We considered local recur-
rence as recurrence at the same site of prior resection. In
addition, we considered recurrence in the ipsilateral lung
a distant recurrence. Recurrence at a remote site in the
remaining ipsilateral lung would not be related to sur-
gical technique given it had been resected in the prior
procedure. Therefore, recurrence in the ipsilateral lung
was analyzed as distant recurrence. Our ﬁndings show
that recurrence at the same site was infrequent, being
seen in two VATS patients and in one thoracotomy
patient; the remainder were distant in both groups. Both
groups showed a similar rate of recurrence, although
recurrence is 12.5% less likely in VATS patients. Several
factors and careful selection of a surgical candidate
remain an inﬂuence on the long-term outcome: ability to
control primary tumor size, absence of other sites of
extrapulmonary metastasis, complete resectability, ade-
quate cardiopulmonary reserve, and technical feasibility
[18]. The implication remains that patients with multiple
lesions should be treated with open thoracotomy, which
does allow palpation of lung tissue and a better
overview.
In addition to location of recurrence, we felt that DFI-1
would give an impression of the accuracy of VATS.
Median DFI-1 was 22 months in the VATS group and
36 months in the open group. Previous studies have shown
a disease-free interval ranging from 31.5 to 37.5 months
[14–16, 21]. The data do not suggest a statistical difference
in DFI-1 (p = 0.07) or DFI-2 (p = 0.53). Given the like-
lihood of recurrence in both groups, we believe that
adjunctive therapies such as chemotherapy and radiation
are also essential to maximize survival. Only 4 of 11 VATS
patients and only 3 of 8 open patients treated with che-
motherapy and/or radiation had recurrence.
Limitations
Despite our classiﬁcation process, we readily admit that our
method has the potential for selection bias. Although there
may be bias to surgeon, each of the four surgeons has a
long history of surgical experience, which almost elimi-
nates any bias related to surgical skill. Another limitation
was the small sample of patients used in this study. One
recommendation for future studies is to increase the sample
size, which will also increase the power of the study. Our
study, similar to previous studies, is a retrospective anal-
ysis of highly selected patients. Potential limitations
include the need to combine patients with nonthoracic
metastasis and those without nonthoracic metastases, and
inability to adequately know whether the primary tumor
was controlled. For a more deﬁnitive evaluation of the
advantages of VATS over open thoracotomy in a long-term
setting, a larger-scale prospective randomized study testing
for equivalence or noninferiority to standard therapy would
be beneﬁcial.
Future and conclusion
VATS has become a viable alternative to open thoracot-
omy for resection of pulmonary metastases. In the cases of
primary adenocarcinoma, VATS shows a reasonable dis-
ease-free interval and shows no additional increase in the
number of thoracic recurrences compared with open tho-
racotomy. Our retrospective study demonstrates that VATS
appears to have better outcome in terms of recurrence rate,
with 5-year recurrence-free survival and median overall
survival comparable to open thoracotomy. Short-term fol-
low-up is encouraging; long-term follow-up will be needed
to conﬁrm these results and to assist in establishing a ﬁnal
conclusion.
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